- Home
- SEMR vs PRAX Comparison
SEMR vs PRAX Comparison
Compare SEMR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- PRAX
- Stock Information
- Founded
- SEMR 2008
- PRAX 2015
- Country
- SEMR United States
- PRAX United States
- Employees
- SEMR N/A
- PRAX N/A
- Industry
- SEMR EDP Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- PRAX Health Care
- Exchange
- SEMR Nasdaq
- PRAX Nasdaq
- Market Cap
- SEMR 1.7B
- PRAX 1.5B
- IPO Year
- SEMR 2021
- PRAX 2020
- Fundamental
- Price
- SEMR $16.67
- PRAX $82.23
- Analyst Decision
- SEMR Buy
- PRAX Strong Buy
- Analyst Count
- SEMR 8
- PRAX 9
- Target Price
- SEMR $17.13
- PRAX $149.11
- AVG Volume (30 Days)
- SEMR 506.5K
- PRAX 309.5K
- Earning Date
- SEMR 03-03-2025
- PRAX 03-04-2025
- Dividend Yield
- SEMR N/A
- PRAX N/A
- EPS Growth
- SEMR N/A
- PRAX N/A
- EPS
- SEMR 0.08
- PRAX N/A
- Revenue
- SEMR $357,567,000.00
- PRAX $1,605,000.00
- Revenue This Year
- SEMR $24.50
- PRAX N/A
- Revenue Next Year
- SEMR $20.36
- PRAX N/A
- P/E Ratio
- SEMR $213.76
- PRAX N/A
- Revenue Growth
- SEMR 22.01
- PRAX N/A
- 52 Week Low
- SEMR $9.64
- PRAX $33.01
- 52 Week High
- SEMR $16.52
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- SEMR 80.11
- PRAX 59.66
- Support Level
- SEMR $11.45
- PRAX $60.07
- Resistance Level
- SEMR $12.10
- PRAX $71.21
- Average True Range (ATR)
- SEMR 0.58
- PRAX 4.38
- MACD
- SEMR 0.58
- PRAX 0.47
- Stochastic Oscillator
- SEMR 96.91
- PRAX 93.90
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the provision of an online visibility management software-as-a-service platform. Its platform enables subscribers to improve their online visibility and drive traffic, including on their websites and social media pages, and distribute highly relevant content to their customers on a targeted basis across various channels to drive high-quality traffic and measure the effectiveness of their digital marketing campaigns. Geographically, it generates revenues from the US, the UK, and other regions.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.